Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

WHAT'S NEW

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, May 11 2023

Full Issue

FDA Advisers Back Approval Of First OTC Birth Control Pill In US

Two advisory panels voted unanimously in support of the FDA allowing Opill, a progestin birth control pill produced by HRA Pharma, to be sold in the U.S. without a prescription. An FDA decision, which is not required to follow the advisers' recommendations, is expected this summer.

The 19th: Over-The-Counter Birth Control Moves One Step Closer To FDA Approval

An influential advisory panel recommended that the Food and Drug Administration (FDA) approve an oral contraceptive pill for over-the-counter use without an age restriction. While hormonal birth control is available without a prescription in many other countries, this medication, Opill, would be the first such option in the United States. (Luthra, 5/10)

NBC News: FDA Panels Back Making Opill Birth Control Pill Available OTC

The 17-0 vote by two advisory panels came despite serious reservations from agency officials about the quality of the data used to support switching the birth control pill, called Opill, from prescription to over the counter. The agency did not have concerns about the safety and effectiveness of the drug. The FDA is not required to follow the recommendation of the committees, though the vote is expected to weigh heavily on its final decision, expected in late summer. (Lovelace Jr., 5/10)

In other reproductive health news —

NPR: A Plastic Sheet With A Pouch Could Be A 'Game Changer' For Maternal Mortality

It's a startling statistic. Every year, 70,000 women around the world basically bleed to death after childbirth. That averages out to nearly 200 deaths a day and makes postpartum hemorrhage a leading cause of maternal deaths. Now a new study points to a surprisingly simple and inexpensive solution: Basically, if the woman lies on a plastic sheet with a small transparent pouch at the other end to collect the blood, the medical team has an immediate sense of how much danger she's in and can take swift action. The cost of the sheet-with-a-pouch: Between $1-2. (Chatterjee, 5/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF